Recombinant Human Papillomavirus Bivalent Vaccine

BIOLOGICAL3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Human Papillomavirus InfectionHuman Papillomavirus-Related Cervical Carcinoma

Phase 3

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

CompletedNCT03728881

National Cancer Institute (NCI)Human Papillomavirus-Related Cervical Carcinoma

Start: 2019-04-01End: 2024-04-23Updated: 2025-08-03

Phase 4

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Active, not recruitingNCT03180034

National Cancer Institute (NCI)Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma

Start: 2017-11-29End: 2028-08-01Updated: 2025-09-04

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial

Active, not recruitingNCT05237947

National Cancer Institute (NCI)Human Papillomavirus-Related Cervical Carcinoma

Start: 2022-03-01End: 2026-05-31Target: 5000Updated: 2026-04-03

Related Papers

Noninferiority of One HPV Vaccine Dose to Two Doses.

2025-12-031 citations

Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial.

2025-07-16

Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial

Vaccine2021-11-2937 citations

Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial.

2021-09-2737 citations

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study.

2020-05-2510 citations

A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.

2019-04-018 citations